Imperial College London
Portrait Picture

Professor Maria Kyrgiou

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Chair in Gynaecologic Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2177m.kyrgiou Website

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Bowden:2022:10.3390/vaccines10101754,
author = {Bowden, S and Ellis, L and Kyrgiou, M and Fiander, AN and Hibbitts, S},
doi = {10.3390/vaccines10101754},
journal = {Vaccines},
title = {High prevalence of HPV 51 in an unvaccinated population and implications for HPV vaccines},
url = {http://dx.doi.org/10.3390/vaccines10101754},
volume = {10},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Human papillomavirus (HPV) is detected in 99.7% of cervical cancers. Current vaccines target types 16 and 18. Prior to vaccination implementation, a prospective cohort study was conducted to determine baseline HPV prevalence in unvaccinated women in Wales; after HPV16 and HPV18, HPV 51 was found to be most prevalent. This study aimed to re-assess the unexpected high prevalence of HPV 51 and consider its potential for type-replacement. Two hundred HPV 51 positive samples underwent re-analysis by repeating the original methodology using HPV 51 GP5+/6+ PCR-enzyme immunoassay, and additionally a novel assay of HPV 51 E7 PCR. Data were correlated with age, social deprivation and cytology. Direct repeat of HPV 51 PCR-EIA identified 146/195 (75.0%) samples as HPV 51 positive; E7 PCR identified 166/195 (85.1%) samples as HPV 51 positive. HPV 51 prevalence increased with cytological grade. The prevalence of HPV 51 in the pre-vaccinated population was truly high. E7 DNA assays may offer increased specificity for HPV genotyping. Cross-protection of current vaccines against less-prevalent HPV types warrants further study. This study highlights the need for longitudinal investigation into the prevalence of non-vaccine HPV types, especially those phylogenetically different to vaccine types for potential type-replacement. Ongoing surveillance will inform future vaccines.
AU  - Bowden,S
AU  - Ellis,L
AU  - Kyrgiou,M
AU  - Fiander,AN
AU  - Hibbitts,S
DO  - 10.3390/vaccines10101754
PY  - 2022///
SN  - 2076-393X
TI  - High prevalence of HPV 51 in an unvaccinated population and implications for HPV vaccines
T2  - Vaccines
UR  - http://dx.doi.org/10.3390/vaccines10101754
UR  - http://hdl.handle.net/10044/1/101037
VL  - 10
ER  -
Download